首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1451795

2024-2032 年獲得性孤兒血液疾病治療市場報告（按治療方法、疾病適應症、配銷通路和地區分類）

Acquired Orphan Blood Diseases Therapeutics Market Report by Therapy, Disease Indication, Distribution Channel, and Region 2024-2032

出版日期: 2024年03月02日 | 出版商:

IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2023年，全球孤兒血液疾病治療藥物市場規模達到88億美元。展望未來， IMARC Group預計到2032年該市場將達到172億美元，2024-2032年複合年成長率（CAGR）為7.5%。個人中血液相關疾病的盛行率不斷上升、政府的積極舉措以及全球醫療基礎設施的改善是推動市場發展的一些關鍵因素。

後天性孤兒血液疾病是一種罕見的血液疾病，是由於血液中無法產生紅血球 (RBC) 或紅血球不足引起的。它們包括許多疾病，如骨髓增生異常症候群（MDS）、特發性血小板減少性紫斑症（ITP）、陣發性睡眠性血紅蛋白尿（PNH）、骨髓纖維化（MF）、真性紅血球增多症（PV ）和後天性粒細胞缺乏症。它們會導致骨髓功能異常並減少血小板數量。由於它們可以透過多種療法進行治療，例如重組因子、免疫球蛋白輸注療法、活化凝血酶原複合物濃縮物和血小板生成素受體激動劑，因此全球對獲得性孤兒血液疾病療法的需求正在上升。

後天性孤兒血液疾病治療市場趨勢：

目前，大眾對血液疾病及其治療方案的認知不斷提高，加上全球個人收入水準的不斷提高，是對市場產生正面影響的主要因素之一。此外，由於老年人口的增加，對血液疾病治療方案的需求不斷成長，正在加強市場的成長。據此，各國的管理機構和私人組織正在透過傳播人們對血液相關疾病發生的認知來鼓勵採用血液疾病治療方法，並在世界各地提供多項醫療保健舉措，從而推動市場的成長。除此之外，由於全球各種血液相關疾病的盛行率不斷增加，血液疾病治療方法的採用越來越多，這提供了積極的市場前景。此外，透過世界各地的線上和線下藥局廣泛獲得孤兒血液疾病治療藥物也促進了市場的成長。除此之外，個人對個人化藥物的需求不斷成長，以及全球醫療保健基礎設施的改善，為行業投資者提供了利潤豐厚的成長機會。除此之外，全球個人對具有成本效益和優質護理解決方案的需求不斷增加。再加上擴大採用預防性護理和健康服務來避免疾病在個人中廣泛傳播，正在推動市場的成長。此外，主要製造商正在為鐮狀細胞性貧血兒科患者推出基於羥基脲的治療方法，這支持了市場的成長。

本報告回答的關鍵問題：

迄今為止，全球獲得性孤兒血液疾病治療市場表現如何，未來幾年將如何表現？
全球獲得性孤兒血液疾病治療市場的促進因素、限制因素和機會是什麼？
每個促進因素、限制因素和機會對全球獲得性孤兒血液疾病治療市場有何影響？
主要區域市場有哪些？
哪些國家代表了最具吸引力的後天孤兒血液疾病治療市場？
基於該療法的市場區隔是什麼？
獲得性孤兒血液疾病治療市場中哪種療法最具吸引力？
根據疾病跡象，市場的細分是什麼？
後天孤兒血液疾病治療市場中最具吸引力的疾病適應症是什麼？
基於配銷通路的市場區隔是什麼？
獲得性孤兒血液疾病治療市場中哪個配銷通路最具吸引力？
全球獲得性孤兒血液疾病治療市場的競爭結構如何？
全球獲得性孤兒血液疾病治療市場的主要參與者/公司有哪些？

後天性粒細胞缺乏症
- 市場走向
- 市場預測
後天性血友病
- 市場走向
- 市場預測
後天性血管性血友病症候群
- 市場走向
- 市場預測
陣發性睡眠性血紅素尿症 (PNH)
- 市場走向
- 市場預測
骨髓造血不良症候群
- 市場走向
- 市場預測
其他
- 市場走向
- 市場預測

第 8 章：市場區隔：按配銷通路

醫院藥房
- 市場走向
- 市場預測
零售藥房
- 市場走向
- 市場預測
其他
- 市場走向
- 市場預測

第 9 章：市場區隔：按地區

北美洲
- 美國
  - 市場走向
  - 市場預測
- 加拿大
  - 市場走向
  - 市場預測
亞太
- 中國
  - 市場走向
  - 市場預測
- 日本
  - 市場走向
  - 市場預測
- 印度
  - 市場走向
  - 市場預測
- 韓國
  - 市場走向
  - 市場預測
- 澳洲
  - 市場走向
  - 市場預測
- 印尼
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
歐洲
- 德國
  - 市場走向
  - 市場預測
- 法國
  - 市場走向
  - 市場預測
- 英國
  - 市場走向
  - 市場預測
- 義大利
  - 市場走向
  - 市場預測
- 西班牙
  - 市場走向
  - 市場預測
- 俄羅斯
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
拉丁美洲
- 巴西
  - 市場走向
  - 市場預測
- 墨西哥
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
中東和非洲
- 市場走向
- 市場細分：按國家/地區
- 市場預測

第 10 章：促進因素、限制與機會

概述
促進要素
限制
機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

概述
買家的議價能力
供應商的議價能力
競爭程度
新進入者的威脅
替代品的威脅

第 13 章：價格分析

第14章：競爭格局

市場結構
關鍵參與者
關鍵參與者簡介
- Alexion Pharmaceuticals Inc. (AstraZeneca plc)
- Amgen Inc.
- GSK plc
- Novartis AG
- Novo Nordisk A/S
- Otsuka Pharmaceutical Co. Ltd.
- Rigel Pharmaceuticals Inc.
- Roche Holding AG
- Sanofi
- Takeda Pharmaceutical Company Limited

簡介目錄圖表

Product Code: SR112024A8217

The global acquired orphan blood diseases therapeutics market size reached US$ 8.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. The growing prevalence of blood-related disorders among individuals, favorable government initiatives, and improving healthcare infrastructure worldwide represent some of the key factors driving the market.

Acquired orphan blood diseases are rare blood conditions that are caused by an inability to produce red blood cells (RBCs) or their insufficiency in the blood. They comprise numerous diseases, such as myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), paroxysmal nocturnal hemoglobinuria (PNH), myelofibrosis (MF), polycythemia vera (PV), and acquired agranulocytosis. They can cause improper functioning of bone marrow and can decrease the number of platelets. As they can be treated through several therapies, such as recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, and thrombopoietin receptor agonists, the demand for acquired orphan blood disease therapeutics is rising across the globe.

Acquired Orphan Blood Diseases Therapeutics Market Trends:

At present, the increasing awareness about blood diseases and their treatment options among the masses, along with the inflating income level of individuals worldwide, represents one of the major factors influencing the market positively. Moreover, the rising demand for blood disease therapeutics options due to the increasing geriatric population is strengthening the growth of the market. In line with this, governing agencies and private organizations of various countries are encouraging the adoption of blood disease therapeutics by spreading awareness about the occurrence of blood-associated disorders among individuals and offering several healthcare initiatives around the world is impelling the growth of the market. Apart from this, the growing adoption of blood disease therapeutics due to the increasing prevalence of various blood-related disorders among individuals across the globe is offering a positive market outlook. Additionally, the wide availability of acquired orphan blood disease therapeutics drugs through online and offline pharmacy stores around the world is contributing to the growth of the market. Besides this, the increasing demand for personalized medicines among individuals, along with the improving healthcare infrastructure worldwide, is offering lucrative growth opportunities to industry investors. In addition to this, there is a rise in the demand for cost-effective and quality care solutions among individuals across the globe. This, coupled with the increasing adoption of preventative care and wellness services to avoid widespread disease among individuals, is bolstering the growth of the market. Furthermore, key manufacturers are introducing hydroxyurea-based treatment for pediatric patients with sickle cell anemia, which is supporting the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global acquired orphan blood diseases therapeutics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on therapy, disease indication, and distribution channel.

Therapy Insights:

Recombinant Factor

Immunoglobulin Infusion Therapy

Activated Prothrombin Complex Concentrate

Thrombopoietin Receptor Agonists

Others

The report has provided a detailed breakup and analysis of the acquired orphan blood diseases therapeutics market based on the therapy. This includes recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, thrombopoietin receptor agonists, and others.

Disease Indication Insights:

Acquired Agranulocytosis

Acquired Hemophilia

Acquired Von Willebrand Syndrome

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Myelodysplastic Syndrome

Others

A detailed breakup and analysis of the acquired orphan blood diseases therapeutics market based on the disease indication has also been provided in the report. This includes acquired agranulocytosis, acquired hemophilia, acquired von willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome, and others. According to the report, acquired hemophilia accounted for the largest market share.

Distribution Channel Insights:

Hospital Pharmacy

Retail Pharmacy

Others

A detailed breakup and analysis of the acquired orphan blood diseases therapeutics market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy, and others. According to the report, hospital pharmacy accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for acquired orphan blood diseases therapeutics. Some of the factors driving the North America acquired orphan blood diseases therapeutics market included the growing awareness about several treatment options, wide availability of therapeutic drugs, favorable government initiatives, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global acquired orphan blood diseases therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global acquired orphan blood diseases therapeutics market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global acquired orphan blood diseases therapeutics market?
What is the impact of each driver, restraint, and opportunity on the global acquired orphan blood diseases therapeutics market?
What are the key regional markets?
Which countries represent the most attractive acquired orphan blood diseases therapeutics market?
What is the breakup of the market based on the therapy?
Which is the most attractive therapy in the acquired orphan blood diseases therapeutics market?
What is the breakup of the market based on the disease indication?
Which is the most attractive disease indication in the acquired orphan blood diseases therapeutics market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the acquired orphan blood diseases therapeutics market?
What is the competitive structure of the global acquired orphan blood diseases therapeutics market?
Who are the key players/companies in the global acquired orphan blood diseases therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Acquired Orphan Blood Diseases Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Therapy

6.1 Recombinant Factor
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Immunoglobulin Infusion Therapy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Activated Prothrombin Complex Concentrate
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Thrombopoietin Receptor Agonists
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Disease Indication

7.1 Acquired Agranulocytosis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Acquired Hemophilia
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Acquired Von Willebrand Syndrome
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Myelodysplastic Syndrome
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Retail Pharmacy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Alexion Pharmaceuticals Inc. (AstraZeneca plc)
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
- 14.3.2 Amgen Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 GSK plc
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Novartis AG
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Novo Nordisk A/S
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Otsuka Pharmaceutical Co. Ltd.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
- 14.3.7 Rigel Pharmaceuticals Inc.
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Roche Holding AG
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
- 14.3.9 Sanofi
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Takeda Pharmaceutical Company Limited
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

簡介目錄圖表

List of Figures

Figure 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Therapy (in %), 2023
Figure 5: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Disease Indication (in %), 2023
Figure 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Distribution Channel (in %), 2023
Figure 7: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Region (in %), 2023
Figure 8: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: North America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: North America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: United States: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: United States: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Canada: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Canada: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: China: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: China: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Japan: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Japan: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: India: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: India: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: South Korea: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: South Korea: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Australia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Australia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Europe: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Europe: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Germany: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Germany: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: France: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: France: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Italy: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Italy: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Spain: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Spain: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Russia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Russia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Latin America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Latin America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Brazil: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Brazil: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Mexico: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Mexico: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Country (in %), 2023
Figure 84: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 85: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Drivers, Restraints, and Opportunities
Figure 86: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Value Chain Analysis
Figure 87: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
Table 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Disease Indication (in Million US$), 2024-2032
Table 4: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 5: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Competitive Structure

02-2729-4219

+886-2-2729-4219